EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)
Exelixis shares fell after the Company reported Q2 revenue of approximately $628.7 million -- below Wall Street consensus -- and lowered its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp.
Exelixis (NASDAQ: EXEL) shares dropped in after-hours trading after the Company reported Q2 revenue of approximately $628.7 million, missing consensus estimates, and lowered and narrowed its full-year 2026 revenue outlook. If you suffered a loss on your Exelixis investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The revenue shortfall came alongside an adjusted EPS beat of $0.91 per share. Investors sold on the top-line number. The Company attributed the reduced full-year outlook to a slower-than-expected ramp in its neuroendocrine-tumor business -- a franchise Exelixis had described to investors as a market-leading position for CABOMETYX in the oral second-line plus segment.
Levi & Korsinsky is investigating potential securities law violations at Exelixis, including whether the Company adequately disclosed the condition of its neuroendocrine-tumor commercial ramp before the guidance reduction. On the May 5, 2026 first quarter earnings call, Chief Financial Officer Christopher Senner stated: "Finally, we are reiterating our full year 2026 financial guidance." That guidance was subsequently lowered.
